Cargando…

HLA-G 3′UTR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer

Polymorphisms in drug-metabolizing enzymes might not completely explain inter-individual differences in toxicity profiles of patients with colorectal cancer (CRC) that receive folinic acid/5-fluorouracil/oxaliplatin (FOLFOX4). Recent data indicate that the immune system could contribute to FOLFOX4 o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garziera, Marica, Virdone, Saverio, De Mattia, Elena, Scarabel, Lucia, Cecchin, Erika, Polesel, Jerry, D’Andrea, Mario, Pella, Nicoletta, Buonadonna, Angela, Favaretto, Adolfo, Toffoli, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5535859/ https://www.ncbi.nlm.nih.gov/pubmed/28653974 http://dx.doi.org/10.3390/ijms18071366

Ejemplares similares

Association of HLA-G 3′UTR Polymorphisms with Response to First-Line FOLFIRI Treatment in Metastatic Colorectal Cancer
por: Scarabel, Lucia, et al.
Publicado: (2022)

HLA-G 3’UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment
por: Garziera, Marica, et al.
Publicado: (2015)

Hypoxic Modulation of HLA-G Expression through the Metabolic Sensor HIF-1 in Human Cancer Cells
por: Garziera, Marica, et al.
Publicado: (2017)

Soluble HLA-G expression levels and HLA-G/irinotecan association in metastatic colorectal cancer treated with irinotecan-based strategy
por: Scarabel, Lucia, et al.
Publicado: (2020)

A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients
por: De Vita, F, et al.
Publicado: (2005)

Fluorouracil/folinic acid/oxaliplatin: Various toxicities: 2 case reports
Publicado: (2021)

Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouracil-oxaliplatin—folinic acid (FOLFOX) for resectable esophageal and junctional cancer: the PROTECT-1402, randomized phase 2 trial
por: Messager, Mathieu, et al.
Publicado: (2016)

Phase I trial of oxaliplatin with fluorouracil, folinic acid and concurrent radiotherapy for oesophageal cancer
por: Conroy, T, et al.
Publicado: (2008)

Experience with adjuvant chemotherapy for pseudomyxoma peritonei secondary to mucinous adenocarcinoma of the appendix with oxaliplatin/fluorouracil/leucovorin (FOLFOX4)
por: Chen, Chin-Fan, et al.
Publicado: (2008)

Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity
por: Fischel, J L, et al.
Publicado: (2002)

Cost-Effectiveness Analysis of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal Cancer
por: Bai, Liangliang, et al.
Publicado: (2019)

Feasibility of Oxaliplatin, Leucovorin, and 5-Fluorouracil (FOLFOX-4) Chemotherapy in Heavily Pretreated Patients with Recurrent Epithelial Ovarian Cancer
por: Lee, Hee Jun, et al.
Publicado: (2013)

Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines
por: Fischel, J-L, et al.
Publicado: (2001)

Colon Cancer Cells Gene Expression Signature As Response to 5- Fluorouracil, Oxaliplatin, and Folinic Acid Treatment
por: Negrei, Carolina, et al.
Publicado: (2016)

Oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) as secondline therapy for patients with advanced urothelial cancer
por: Zhang, Sheng, et al.
Publicado: (2016)

Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer
por: Conteduca, Vincenza, et al.
Publicado: (2018)

Role of oxaliplatin combined with 5-fluorouracil and folinic acid in the first- and second-line treatment of advanced colorectal cancer
por: Jonker, D., et al.
Publicado: (2006)

Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment
por: Zoetemelk, Marloes, et al.
Publicado: (2020)

Sex Disparities in Efficacy in COVID-19 Vaccines: A Systematic Review and Meta-Analysis
por: Bignucolo, Alessia, et al.
Publicado: (2021)

Folinic Acid, Fluorouracil, and Oxaliplatin Therapy for Recurrent Esophageal Cancer with Syndrome of Inadequate Antidiuretic Hormone Secretion (SIADH) After Preoperative Cisplatin/5-Fluorouracil Therapy
por: Futai, Ryoko, et al.
Publicado: (2022)

A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients
por: Garufi, C, et al.
Publicado: (2003)

Efficacy and Safety of Oxaliplatin, 5-Fluorouracil, and Folinic Acid Combination Chemotherapy as First-Line Treatment in Metastatic or Recurrent Gastric Cancer
por: Kim, Han Jo, et al.
Publicado: (2011)

Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial
por: Qin, Shukui, et al.
Publicado: (2018)

Interstitial lung disease in a patient treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) for metastatic colorectal cancer
por: Hannan, Liam M, et al.
Publicado: (2012)

A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer
por: Gravalos, Cristina, et al.
Publicado: (2012)

5-Fluorouracil and folinic acid: interesting biochemistry or effective treatment?
por: Kerr, D. J.
Publicado: (1989)

Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer
por: Lordick, F, et al.
Publicado: (2005)

Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer
por: Chao, Y, et al.
Publicado: (2004)

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)
por: Souglakos, J, et al.
Publicado: (2006)

Clonal Evolution of TP53 c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC)
por: Garziera, Marica, et al.
Publicado: (2019)

Treatment of neuroendocrine tumours with infusional 5-fluorouracil, folinic acid and streptozocin
por: Gonzalez, M A, et al.
Publicado: (2003)

A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma
por: Correale, P, et al.
Publicado: (2004)

Spontaneous Aortic Haematoma in a Patient Receiving Adjuvant Folinic Acid, 5-Fluorouracil, Irinotecan, and Oxaliplatin Chemotherapy Following Resection of a Pancreatic Adenocarcinoma
por: Dacie, Ruth, et al.
Publicado: (2020)

Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer
por: Conroy, T, et al.
Publicado: (2010)

A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy
por: De Mattia, Elena, et al.
Publicado: (2018)

Combined effects of 5-Fluorouracil, Folinic acid and Oxaliplatin on the expression of carcinoembryonic antigen in human colon cancer cells: pharmacological basis to develop an active antitumor immunochemotherapy
por: Prete, Salvatore P, et al.
Publicado: (2008)

Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial
por: Santini, D, et al.
Publicado: (2006)

5-fluorouracil and folinic acid-induced mucositis: no effect of oral glutamine supplementation.
por: Jebb, S. A., et al.
Publicado: (1994)

Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS)
por: Garziera, Marica, et al.
Publicado: (2018)

Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212)
por: Modest, Dominik Paul, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dvhm39f30ht8f4r2ja6sq54vik